Cetuximab (Erbitux) – an emerging targeted therapy for epidermal growth factor receptor‐expressing tumours
作者： M. Ng , D. Cunningham
DOI: 10.1111/J.1368-5031.2004.00369.X
关键词:
摘要: Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours The receptor (EGFR) provides a rational target cancer as it is commonly over-expressed in variety of solid tumours, and deregulation its activity associated with resistance to chemotherapy radiotherapy poorer prognosis. new monoclonal chimeric antibody directed against the EGFR. It has demonstrable number tumour types both combination on own. potential combine cetuximab increase efficacy without significantly increasing toxicity exciting advancement treatment cancers.
core.ac.uk
sci-hub.se 参考文章(38)
Tony DeBlasio, Mark Rubin, Zhen Fan, Andrew Koff, Tim Soos, John Mendelsohn, Xipu Wu, Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. ,vol. 12, pp. 1397- 1403 ,(1996)
Z Fan, Y Lu, X Wu, J Mendelsohn, Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry. ,vol. 269, pp. 27595- 27602 ,(1994) , 10.1016/S0021-9258(18)47026-3
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
G Carpenter, S Cohen, Epidermal growth factor. Journal of Biological Chemistry. ,vol. 265, pp. 7709- 7712 ,(1972) , 10.1016/S0021-9258(19)38983-5
Norbert Prenzel, Esther Zwick, Henrik Daub, Michael Leserer, Reimar Abraham, Christian Wallasch, Axel Ullrich, EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF Nature. ,vol. 402, pp. 884- 888 ,(1999) , 10.1038/47260
Brian Fendly, Mien Chie Hung, Robert S. Kerbel, Alicia M. Viloria Petit, Patricia Rockwell, Neil Goldstein, Janusz Rak, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. ,vol. 151, pp. 1523- 1530 ,(1997)
M.W. Pedersen, M. Meltorn, L. Damstrup, H.S. Poulsen, The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy Annals of Oncology. ,vol. 12, pp. 745- 760 ,(2001) , 10.1023/A:1011177318162
J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D’Andrea, A. Seidman, L. Norton, K. Gunnett, J. Falcey, V. Anderson, H. Waksal, J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology. ,vol. 18, pp. 904- 914 ,(2000) , 10.1200/JCO.2000.18.4.904
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Motoo Nagane, Yoshitaka Narita, Kazuhiko Mishima, Alexander Levitzki, Antony W. Burgess, Webster K. Cavenee, H. J. Su Huang, Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor Journal of Neurosurgery. ,vol. 95, pp. 472- 479 ,(2001) , 10.3171/JNS.2001.95.3.0472